Troglitazone Compounds for Treating Climacteric and Cancer

Inventors: Randall J. Uban, Allan Green

Description:
The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPAR.gamma.). Troglitazone and related compounds can therefore be used to prevent excessive uterine bleeding during. Further, enhanced translocation of this orphan nuclear receptor into the nucleus of cells will block transcription in rapidly proliferating cancer cells that express PPAR.gamma., resulting in loss of cell viability

Patent Status: US 6207690, 6579893

Contact:
Sundeep Mattamana, Ph.D.
Associate Director
Office of Technology Transfer
(409) 772-0374
sumattam@utmb.edu